Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled Single-Ascending Dose and Multiple-Ascending Dose Phase 1 Study of SL-325 in Healthy Volunteers

Next Previous
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Single-Ascending Dose and Multiple-Ascending Dose Phase 1 Study of SL-325 in Healthy Volunteers

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 19 Sep 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SL 325 (Primary)
  • Indications Inflammatory bowel diseases
  • Focus Adverse reactions; First in man
  • Sponsors Shattuck Labs

Most Recent Events

  • 05 Aug 2025 According to Shattuck Labs Media Release, company announced oversubscribed private placement of up to approximately $103 million. The accompanying common stock warrants are immediately exercisable and expire 30 days after a public announcement of the data from the Phase 1 clinical trial for SL-325 in healthy volunteers and the design of its Phase 2 clinical trials.
  • 05 Aug 2025 According to Shattuck Labs Media Release, enrollment in our Phase 1 clinical trial for SL-325 is expected to begin this quarter.
  • 01 May 2025 According to Shattuck Labs Media Release, First patient in for the SAD portion of the trial expected in the third quarter of 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top